Indian Journal of Hematology and Blood Transfusion最新文献_第6页

Imatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case–control Study 甲磺酸伊马替尼对慢性髓性白血病患者造成潜在心功能障碍：病例对照研究的结果

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-07-08 DOI: 10.1007/s12288-024-01797-9

Gowri Shankar, Ankur Jain, Ankur Gupta, Aditya Jandial, Neelam Varma, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra

{"title":"Imatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case–control Study","authors":"Gowri Shankar, Ankur Jain, Ankur Gupta, Aditya Jandial, Neelam Varma, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra","doi":"10.1007/s12288-024-01797-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01797-9","url":null,"abstract":"Unlike second-generation tyrosine kinase inhibitors, effects of imatinib on the cardiovascular (CV) system are debatable. The current case–control study aimed to evaluate the CV effects of imatinib in patients with chronic myeloid leukemia (CML) using non-invasive 2D-echocardiography testing. Patients with CML ≥ 13 years attending the adult haematology clinic of a tertiary care hospital in north India were prospectively enrolled over 1.5 years. The study population (n = 110) consisted of 35 newly diagnosed patients (treatment-naïve group) and 75 patients under imatinib therapy ≥ 1 year (treated group). All the eligible patients were subjected to 2D-echocardiography to calculate pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF) and deceleration time (DT). These parameters were compared between the two groups. P-value < 0.05 was considered statistically significant. The median age of study population was 40 years (range, 13–73) and M:F ratio was 1.14:1. Both the groups had similar demographics at the diagnosis including CV risk factors. The median PASP of the treated group was 2 mm Hg higher than the treatment-naïve group (25 vs 23 mm Hg, p-value = 0.919). The median LVEF of the treated group was 3.2% lower than the treatment-naïve group (58.5% vs 61.72%, p-value = 0.577). The median DT of the treated group was 7 ms shorter than treatment-naïve group (211 vs 204 ms, p-value = 0.411). Imatinib causes potential cardiac dysfunction in patients with CML. Large scale prospective follow-up trials in the same cohort of patients are needed to validate the findings of our study.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141576386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of the Rate and Reasons for Discard Blood and Its Components from 2019 to 2022 in a Single Blood Service in China 2019-2022年中国单采血站血液及其成分弃血率及原因分析

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-07-02 DOI: 10.1007/s12288-024-01813-y

Hong Zhu, Wenjuan Han, Liwei Zhu, Ying Lu, Zhuolan Shen, Wenyan Guo, Wei Ding, Faming Zhu

{"title":"Analysis of the Rate and Reasons for Discard Blood and Its Components from 2019 to 2022 in a Single Blood Service in China","authors":"Hong Zhu, Wenjuan Han, Liwei Zhu, Ying Lu, Zhuolan Shen, Wenyan Guo, Wei Ding, Faming Zhu","doi":"10.1007/s12288-024-01813-y","DOIUrl":"https://doi.org/10.1007/s12288-024-01813-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3>The discard rate of blood services as a crucial quality metric for monitoring and enhancing blood safety within blood bank operations. This study investigated the prevalence and underlying causes of discarded blood and its associated components at a blood center in China.<h3 data-test=\"abstract-sub-heading\">Materials and Methods</h3>This retrospective analysis examined data pertaining to discarded blood and its components from 2019 to 2022. Information was retrieved from the blood center's electronic blood information management system.<h3 data-test=\"abstract-sub-heading\">Results</h3>A total of 71,346 units of whole blood and blood components (representing a discard rate of 2.34%) were discarded. The discard rates exhibited variation across different blood components: whole blood (0.15%), red blood cells (2.24%), fresh frozen plasma (4.20%), frozen plasma (5.05%), cryoprecipitate antihemophilic factor (0.91%), platelets (0.33%), and washed red blood cells (0.03%). Statistical analysis revealed a significant association (P < 0.05) between the reasons for discarding blood and the actual discard events.<h3 data-test=\"abstract-sub-heading\">Conclusion</h3>This study presents a comparative analysis of discard rates and their corresponding justifications within a single blood center in China. The findings contribute to the advancement of quality control measures for blood and its components within blood service operations.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congenital Dyserythropoietic Anaemia Type II with SEC23B Mutation in Adults: A Case Series 成人 SEC23B 基因突变导致的先天性 II 型红细胞生成障碍性贫血：病例系列

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-07-01 DOI: 10.1007/s12288-024-01806-x

Priyanka Moule, Deepika Gupta, Chetan Agarwal, Sabina Langer, Amrita Saraf, Jyoti Kotwal, Nitin Gupta

引用次数: 0

Daily Versus Alternate Day Oral Iron Replacement for Women with Iron Deficiency Anaemia: A Randomized Controlled Trial 缺铁性贫血妇女每日口服铁剂还是隔日口服铁剂？随机对照试验

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-29 DOI: 10.1007/s12288-024-01816-9

Mallesh Dhanush, Kolar Vishwanath Vinod, Prabhu Manivannan, Prashant S. Adole, Dhanajayan Govindan

{"title":"Daily Versus Alternate Day Oral Iron Replacement for Women with Iron Deficiency Anaemia: A Randomized Controlled Trial","authors":"Mallesh Dhanush, Kolar Vishwanath Vinod, Prabhu Manivannan, Prashant S. Adole, Dhanajayan Govindan","doi":"10.1007/s12288-024-01816-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01816-9","url":null,"abstract":"The optimal way of oral iron replacement for iron deficiency anaemia(IDA) is still unknown and few recent studies have reported better fractional absorption and tolerability of intermittently administered iron. This randomised, active comparator controlled, open-label trial evaluated efficacy and tolerability of 120 mg elemental iron (2 × 200 mg ferrous sulphate tablets) administered as a single dose on alternate days (alternate-day arm, ADA) vis-à-vis 60 mg elemental iron (single FeSO4 tablet) administered daily (daily arm, DA), among women (age ≥ 18 years) having IDA, with haemoglobin (Hb) concentration between 6 and 10 g/dL and serum ferritin < 30 µg/L. Primary outcome was the Hb change on Day-28. Secondary outcomes included Hb change on Day-56, change in serum hepcidin levels from baseline to Day-14, adverse effects (AEs) and compliance to treatment. Sixty-eight participants (34 each in DA and ADA) were enrolled in the trial. Hb change at Day-28 was significantly higher in the ADA compared to DA (mean change: +2.2 ± 1.3 vs. +1.3 ± 1.1 g/dL, p = 0.003). Though Hb increment at Day-56 was also higher in ADA, it was not statistically significant. There was no significant difference in changes in serum hepcidin from baseline to Day-14 between the arms. Significantly higher proportion in the DA had AEs compared to ADA (45% vs. 9%, p < 0.005). However, treatment compliance was not significantly different between the arms. Alternate-day oral iron replacement led to significantly higher haemoglobin increment in the short run and caused significantly lesser AEs compared to daily replacement. Larger multicentric RCTs with longer duration of intervention should evaluate alternate-day replacement vis-à-vis daily therapy in future. This randomised controlled trial has been registered in Clinical Trial Registry-India (CTRI Reg. No.: CTRI/2021/12/038370, dated 2nd December 2021).","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence of CAR-T Cell Expansion in Peripheral Blood by Unusual Lymphoid Morphology: A Relatively Unexplored Phenomenon Post CAR-T Infusion CAR-T细胞通过异常淋巴形态在外周血中扩增的证据：CAR-T输注后一种尚未被探索的现象

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-28 DOI: 10.1007/s12288-024-01815-w

Nupur Das, Prashant Mehta, Pravas Mishra, Swati Pabbi, Rahul Katharia, Tanisha Singla, Saphalta Baghmar

引用次数: 0

Genotyping R1336X and Eliminating the Pseudogene Amplification in Type 3 von Willebrand Disease Patients 对 3 型 von Willebrand 病患者进行 R1336X 基因分型并消除伪基因扩增

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-24 DOI: 10.1007/s12288-024-01798-8

Mahmoud Khatib, Azam Bolhassani, Zahra Noormohammadi, Maryam Ghazizadeh

{"title":"Genotyping R1336X and Eliminating the Pseudogene Amplification in Type 3 von Willebrand Disease Patients","authors":"Mahmoud Khatib, Azam Bolhassani, Zahra Noormohammadi, Maryam Ghazizadeh","doi":"10.1007/s12288-024-01798-8","DOIUrl":"https://doi.org/10.1007/s12288-024-01798-8","url":null,"abstract":"Among inherited bleeding disorders, von Willebrand disease (VWD) is the most common disease worldwide. Type 3, the most severe form, is more prevalent in developing countries primarily due to consanguineous marriages. The enormous size of the von Willebrand factor gene, different kinds of mutations, and a partial unprocessed pseudogene make variation detection more difficult. To distinguish the VWF gene and the pseudogene sequence and prevent pseudogene amplification, it is necessary to utilize a suitable method. In this study, 42 unrelated VWD type 3 patients and 22 normal controls were included. Tetra-primer ARMS-PCR was applied for genotyping the single nucleotide variation, R1336X located on exon 28, which overlaps the pseudogene. The High percentage of heterozygotes (17% in VWD patients and 13% in controls) raised the suspicion of concomitant amplification of the VWF gene and it's pseudogene due to similarity in their primer-binding site sequence. To overcome this issue, we applied a two-step method using touch-down PCR followed by a tetra-primer ARMS-PCR. All cases with the heterozygous pattern on the first tetra-primer ARMS PCR were found to be normal homozygotes. In type 3 VWD patients genotyping is essential in decreasing the incidence of the disease, but the presence of a pseudogene with 97% homology makes it difficult. Applying appropriate methods that combine touch-down PCR and tetra-primer ARMS-PCR in terms of reliability, sensitivity, and accuracy can help to eliminate the pseudogene effect and diagnose more affected individuals.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renomegaly as a Presentation of T-Acute Lymphoblastic Leukemia 肾脏肿大是 T 型急性淋巴细胞白血病的一种表现形式

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-22 DOI: 10.1007/s12288-024-01810-1

Sarthak Wadhera, Rudra Narayan Swain, Shashikant Saini, Charanpreet Singh, Arihant Jain, Prashant Sharma, Gaurav Prakash, Aravind Sekar, Alka Khadwal, Pankaj Malhotra

引用次数: 0

Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population 除 BCR-ABL 外，体细胞突变分析在 CML 中的意义：印度人群的回顾性研究

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-21 DOI: 10.1007/s12288-024-01808-9

Pooja Chaudhary, Spandan Chaudhary, Falguni Patel, Shiv Patel, Dhiren Patel, Lokesh Patel, Nikha Trivedi, Toral Vaishnani, Ekta Jajodia, Firoz Ahmad, Neeraj Arora

{"title":"Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population","authors":"Pooja Chaudhary, Spandan Chaudhary, Falguni Patel, Shiv Patel, Dhiren Patel, Lokesh Patel, Nikha Trivedi, Toral Vaishnani, Ekta Jajodia, Firoz Ahmad, Neeraj Arora","doi":"10.1007/s12288-024-01808-9","DOIUrl":"https://doi.org/10.1007/s12288-024-01808-9","url":null,"abstract":"Somatic mutation and fusion detection in acute myeloid leukemia to determine disease subtype and treatment regime is a common practice, but it’s not yet employed in chronic myeloid leukemia (CML). CML is still monitored by routine quantitative determination of the BCR-ABL fusion transcript and treated with tyrosine kinase inhibitors (TKIs). Despite the availability of the three generations of TKIs, resistance and progression in CML pathogenesis suggest a strong role for somatic mutations. The present study aimed to identify the role of somatic mutation profiling in CML patients in disease management. 196 CML patient samples were used in this investigation, comprising 26 CML-BP, 8 CML-AP, and 162 CML-CP samples. Following cytogenetic analysis for confirmation, each sample was sequenced utilizing the Ion Torrent platform by a targeted panel. Of the 196 CML samples, 81 (41.33%) had 125 variations affecting 27 genes, while 115 (58.67%) harboured no mutations. The study revealed that ASXL1 (31.2%), ABL1 (14.4%), and TET2 (8.8%) were the most frequently altered genes. These genes are recognized indicators of CML disease. Few samples found with mutated GATA2, IDH1, NRAS, SETBP1, WT1, PHF6, KIT, etc. and fusions like RUNX1(5)-MECOM (2) and CBFB- MYH11 are indicative of disease progression. The outcome of this study suggests that mutational profiling of CML patients can help in the prognostication of disease. Based on the results of the study, the authors have also provided possible future risk stratification and diagnosis workflow for CML disease.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data 输血依赖型β地中海贫血患儿的双重口服铁螯合剂 (DOIC)：真实世界的疗效数据

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-20 DOI: 10.1007/s12288-024-01804-z

Amitoj Singh Chadha, Abaan Ul Haq Khazi Mohammad, Naveen Kanth Dhãmi Nadakuditi, Surbhi Agrawal, Kenson Sam Alex, Namratha S. Naik, John Michael Raj, Anand Prakash

{"title":"Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data","authors":"Amitoj Singh Chadha, Abaan Ul Haq Khazi Mohammad, Naveen Kanth Dhãmi Nadakuditi, Surbhi Agrawal, Kenson Sam Alex, Namratha S. Naik, John Michael Raj, Anand Prakash","doi":"10.1007/s12288-024-01804-z","DOIUrl":"https://doi.org/10.1007/s12288-024-01804-z","url":null,"abstract":"Combination chelation with deferiprone (DFP) and deferasirox (DFX) is one of the treatment modalities for iron overload in children with Transfusion-dependent Thalassemia (TDT). We report our experience with dual oral iron chelation. Retrospective chart review was conducted on all children started on Dual Oral Iron Chelation (DOIC) from 2015 to 2022. Children with TDT requiring DOIC were included in the study. Forty-five children required DOIC. The mean SF before DOIC initiation was 2929 ng/dl (SD 1465.07). The mean ferritin following DOIC was 1962.10 ng/dl (SD 1165.83) at 30 months. Mean duration on DOIC was 44.6 months (IQR 60–30). With DOIC, 82.22% children had a fall in ferritin to < 2000 ng/dl and in 60% of them had fall to < 1000 ng/dL. Dual Oral Iron Chelation (DOIC) is efficacious in reducing ferritin in iron-overloaded patients. Higher ferritin values (> 2500 ng/dL) drop rapidly in the first 12–24 months. DOIC was well-tolerated with no severe adverse effects.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Mutational Changes of Autophagy Marker LC3A in Patients with Acute Myeloid Leukemia; Effect of DNA Methylation and Expression Level of LncRNA-GAS5 and miRNA-155-5p, A Case Control Study 急性髓性白血病患者自噬标记物 LC3A 的非突变变化；DNA 甲基化及 LncRNA-GAS5 和 miRNA-155-5p 表达水平的影响，一项病例对照研究

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-06-18 DOI: 10.1007/s12288-024-01765-3

Vahid Amiri, Amin Mirzaeian, Ali Noroozi-Aghideh

{"title":"Non-Mutational Changes of Autophagy Marker LC3A in Patients with Acute Myeloid Leukemia; Effect of DNA Methylation and Expression Level of LncRNA-GAS5 and miRNA-155-5p, A Case Control Study","authors":"Vahid Amiri, Amin Mirzaeian, Ali Noroozi-Aghideh","doi":"10.1007/s12288-024-01765-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01765-3","url":null,"abstract":"Clinical translation of autophagy modulators is tied to thoroughly acquainted with the precise state of this process and its regulators in a particular cancer. LC3Av1 is a marker of autophagosome membrane that has been contributed with pathobiology of myriad of human cancers. In the present study, we examined the effect of promoter methylation and miR-155 and LncRNA-GAS5 (GAS5) expression levels on transcription of LC3Av1 in AML patients. The study included 60 patients with de novo AML and 20 subjects with normal bone marrow cellular composition. Methylation-Sensitive high resolution melting (MS-HRM) was performed for analysis of LC3Av1 CpG island methylation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for assessing LC3Av1, GAS5 and miR-155 expression levels. There was a significant elevation in the expression level of miR-155 and repression of LC3Av1 in AML samples. We found that LC3Av1 downregulation was negatively associated with its CpG island hypermethylation and miR-155 expression. Aging leads to overexpression of LC3Av1. GAS5 neither was differently expressed in AML patients compared to control samples nor has been related to LC3Av1 expression. The present study revealed that epigenetic changes like DNA methylation and alteration of miR-155 have a pivotal role in repression of autophagy marker LC3Av1, which potentially could provide the important clues of prognostic and therapeutic targets. The optimal strategies for clinical implementation of autophagy in AML is yet to be fully achieved and deserve further studies.","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141506495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0